Design of a Novel Cyclotide-Based CXCR4 Antagonist with Anti-Human Immunodeficiency Virus (HIV)-1 Activity

Journal of Medicinal Chemistry (Impact Factor: 5.45). 11/2012; 55(23). DOI: 10.1021/jm301468k
Source: PubMed


Herein, we report for the first time the design and synthesis of a novel cyclotide able to efficiently inhibit HIV-1 viral replication by selectively targeting cytokine receptor CXCR4. This was accomplished by grafting a series of topologically modified CVX15 based peptides onto the loop 6 of cyclotide MCoTI-I. The most active compound produced in this study was a potent CXCR4 antagonist (EC50 ≈ 20 nM) and an efficient HIV-1 cell-entry blocker (EC50 ≈ 2 nM). This cyclotide also showed high stability in human serum thereby providing a promising lead compound for the design of a novel type of peptide-based anti-cancer and anti-HIV-1 therapeutics.

Download full-text


Available from: Julio A Camarero, Jan 16, 2015
  • Source
    • "As both peptides have the ability to enter cells (Greenwood et al. 2007; Cascales et al. 2011; Contreras et al. 2011; D'Souza et al. 2014), they have been touted as potential vectors for the delivery of grafted epitopes with desired activities to intracellular targets (Ji et al. 2013). Examples of grafting applications include engineering of: (i) MCoTI-I into an anti-HIV agent (Aboye et al. 2012) and an antagonist of intracellular proteins Hdm2 and HdmX for suppressing tumor growth (Ji et al. 2013) and (ii) MCoTI-II into a β-tryptase inhibitor (Thongyoo et al. 2009; Sommerhoff et al. 2010) and human leukocyte elastase inhibitor (Thongyoo et al. 2009) for inflammatory disorders, and a pro-angiogenic agent for wound healing (Chan et al. 2011). Despite these remarkable successes, the introduction of new activities onto the Momordica cyclic peptide scaffold remains challenging because the limiting structural and functional constraints are not yet fully understood. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cyclic proteins have evolved for millions of years across all kingdoms of life to confer structural stability over their acyclic counterparts while maintaining intrinsic functional properties. Here, we show that cyclic miniproteins (or peptides) from Momordica (Cucurbitaceae) seeds evolved in species that diverged from an African ancestor around 19 Ma. The ability to achieve head-to-tail cyclization of Momordica cyclic peptides appears to have been acquired through a series of mutations in their acyclic precursor coding sequences following recent and independent gene expansion event(s). Evolutionary analysis of Momordica cyclic peptides reveals sites that are under selection, highlighting residues that are presumably constrained for maintaining their function as potent trypsin inhibitors. Molecular dynamics of Momordica cyclic peptides in complex with trypsin reveals site-specific residues involved in target binding. In a broader context, this study provides a basis for selecting Momordica species to further investigate the biosynthesis of the cyclic peptides and for constructing libraries that may be screened against evolutionarily related serine proteases implicated in human diseases.
    Molecular Biology and Evolution 11/2014; 32(2). DOI:10.1093/molbev/msu307 · 9.11 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Human immunodeficiency virus (HIV) afflicts an estimated 30 million people globally, making it a continuing pandemic. Despite major research efforts, the rate of new infections has remained relatively static over time. This article reviews an emerging strategy for the treatment of HIV, the inhibition of the co-receptors necessary for HIV entry, CCR5 and CXCR4. The aim of this article is to highlight potential therapeutics derived from peptides and proteins that show particular promise in HIV treatment. Molecules that act on CCR5, CXCR4 or on both receptors will be discussed herein.
    Experimental Biology and Medicine 05/2013; 238(5):442-9. DOI:10.1177/1535370213480696 · 2.17 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A selective N→S acyl transfer reaction facilitates semi-synthesis of the plant cyclotide kalata B1 from a linear precursor peptide of bacterial origin, through simple appendage of N-terminal cysteine and a thiol-labile C-terminal Gly-Cys motif. This constitutes the first synthesis of a ribosomally derived circular miniprotein, without recourse to protein splicing elements.
    ChemBioChem 05/2013; 14(7). DOI:10.1002/cbic.201300105 · 3.09 Impact Factor
Show more